Anxiolytic-, antidepressant- and anticonvulsant-like effects of the alkaloid montanine isolated from Hippeastrum vittatum

Pharmacology Biochemistry and Behavior

Volumn 85, Issue 1, 2006, Pages 148-154

  da Silva, Ana Flávia Schürmann ^a   de Andrade, Jean Paulo ^a   Bevilaqua, Lia R M ^a,b   de Souza, Márcia Maria ^c   Izquierdo, Ivan ^b   Henriques, Amélia Teresinha ^a   Zuanazzi, José Ângelo Silveira ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c UNIVERSIDADE DO VALE DO ITAJAÍ   (Brazil)

Author keywords

Alkaloid; Amaryllidaceae; Anxiety; Convulsion; Depression; Hippeastrum; Memory; Montanine

Indexed keywords

ALKALOID DERIVATIVE; AMARYLLIDACEAE ALKALOID; MONTANINE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTICONVULSANT ACTIVITY; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; CONVULSION; DOSE RESPONSE; DRUG ACTIVITY; DRUG ISOLATION; FEMALE; HIPPEASTRUM VITTATUM; LD 50; MALE; MAZE TEST; MEMORY CONSOLIDATION; MOUSE; NONHUMAN; PLANT; PRIORITY JOURNAL; RAT; SEX RATIO; SLEEP; SWIMMING; TOXICITY TESTING; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; ISOQUINOLINES; LILIACEAE; MICE; RATS; RATS, WISTAR;

AMARYLLIDACEAE; HIPPEASTRUM; HIPPEASTRUM VITTATUM;

EID: 33751349973     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2006.07.027     Document Type: Article

References (56)

1. Anisman H., and Matheson K. Stress, depression, and anhedonia: caveats concerning animal models. Neurosci Biobehav Rev 29 (2005) 525-546
2. Bevilaqua L.R., da Silva W.N., Medina J.H., Izquierdo I., and Cammarota M. Extinction and reacquisition of a fear-motivated memory require activity of the Src family of tyrosine kinases in the CA1 region of the hippocampus. Pharmacol Biochem Behav 81 (2005) 139-145
3. Cammarota M., Bernabeu R., Levi De Stein M., Izquierdo I., and Medina J.H. Learning-specific, time-dependent increases in hippocampal Ca2+/calmodulin-dependent protein kinase II activity and AMPA GluR1 subunit immunoreactivity. Eur J Neurosci 10 (1998) 2669-2676
4. Cammarota M., Bevilaqua L.R., Ardenghi P., Paratcha G., Levi de Stein M., Izquierdo I., et al. Learning-associated activation of nuclear MAPK, CREB and Elk-1, along with Fos production, in the rat hippocampus after a one-trial avoidance learning: abolition by NMDA receptor blockade. Mol Brain Res 76 (2000) 36-46
5. Cammarota M., Bevilaqua L.R., Kerr D., Medina J.H., and Izquierdo I. Inhibition of mRNA and protein synthesis in the CA1 region of the dorsal hippocampus blocks reinstallment of an extinguished conditioned fear response. J Neurosci 23 (2003) 737-741
6. Cammarota M., Bevilaqua L.R., Kohler C., Medina J.H., and Izquierdo I. Learning twice is different from learning once and from learning more. Neuroscience 132 (2005) 273-279
7. Campos M.M., Fernandes E.S., Ferreira J., Bortolanza L.B., Santos A.R., and Calixto J.B. Pharmacological and neurochemical evidence for antidepressant-like effects of the herbal product Catuama. Pharmacol Biochem Behav 78 (2004) 757-764
8. Chopin P., Stenger A., Couzinier J.P., and Briley M. Indirect dopaminergic effects of tofisopam, a 2,3-benzodiazepine, and their inhibition by lithium. J Pharm Pharmacol 37 (1985) 917-919
9. Costa-Campos L., Dassoler S.C., Rigo A.P., Iwu M., and Elisabetsky E. Anxiolytic properties of the antipsychotic alkaloid alstonine. Pharmacol Biochem Behav 77 (2004) 481-489
10. Da Silva W.C., Bonini J.S., Bevilaqua L.R., Izquierdo I., and Cammarota M. Histamine enhances inhibitory avoidance memory consolidation through a H2 receptor-dependent mechanism. Neurobiol Learn Mem 86 (2006) 100-106
11. Elgorashi E.E., Stafford G.I., and Van Staden J. Pharmacological screening of six Amaryllidaceae species. Planta Med (2004) 260-262
12. Elgorashi E.E., Stafford G.I., Jager A.K., and van Staden J. Inhibition of [3H]citalopram binding to the rat brain serotonin transporter by Amaryllidaceae alkaloids. Planta Med 72 (2006) 470-473
13. Evidente A., Andolfi A., Abou-Donia A.H., Touema S.M., Hammoda H.M., Shawky E., et al. (-)-Amarbellisine, a lycorine-type alkaloid from Amaryllis belladonna L. growing in Egypt. Phytochemistry 65 (2004) 2113-2118
14. Fennell C.W., Elgorashi E.E., and van Staden J. Alkaloid production in Crinum moorei cultures. J Nat Prod 66 (2003) 1524-1526
15. Galea L.A., Wide J.K., and Barr A.M. Estradiol alleviates depressive-like symptoms in a novel animal model of post-partum depression. Behav Brain Res 122 (2001) 1-9
16. Heinrich M., and Lee Teoh H. Galanthamine from snowdrop-the development of a modern drug against Alzheimer's disease from local Caucasian knowledge. J Ethnopharmacol 92 (2004) 147-162
17. Hinojosa F.R., Spricigo Jr. L., Izidio G.S., Bruske G.R., Lopes D.M., and Ramos A. Evaluation of two genetic animal models in behavioral tests of anxiety and depression. Behav Brain Res 168 (2006) 127-136
18. Hofmann Jr. A.E., Sebben C., Sobral M.E.G., Dutilh J.H.A., Henriques A.T., and Zuanazzi J.A.S. Alkaloids of Hippeastrum glaucescens. Biochem Syst Ecol 31 (2003) 1455-1456
19. Houghton P.J., Agbedahunsi J.M., and Adegbulugbe A. Choline esterase inhibitory properties of alkaloids from two Nigerian Crinum species. Phytochemistry 65 (2004) 2893-2896
20. Ito M., Ohmori I., Nakahori T., Ouchida M., and Ohtsuka Y. Mutation screen of GABRA1, GABRB2 and GABRG2 genes in Japanese patients with absence seizures. Neurosci Lett 383 (2005) 220-224
21. Izquierdo I., Cammarota M., Medina J.H., and Bevilaqua L.R. Pharmacological findings on the biochemical bases of memory processes: a general view. Neural Plast 11 (2004) 159-189
22. Jackson M.J., and Turkington D. Depression and anxiety in epilepsy. J Neurol Neurosurg Psychiatry 76 (2005) 45-47
23. Jiang Y., Li H., Li P., Cai Z., and Ye W. Steroidal alkaloids from the bulbs of Fritillaria puqiensis. J Nat Prod 68 (2005) 264-267
24. Kaya G.I., and Gozler B. Quantitative and cytotoxic activity determinations on Galanthus nivalis subsp. cilicicus. Fitoterapia 76 (2005) 340-343
25. Kerr D.S., Bevilaqua L.R., Bonini J.S., Rossato J.I., Kohler C.A., Medina J.H., et al. Angiotensin II blocks memory consolidation through an AT2 receptor-dependent mechanism. Psychopharmacology 179 (2005) 529-535
26. Labrana J., Machocho A.K., Kricsfalusy V., Brun R., Codina C., Viladomat F., et al. Alkaloids from Narcissus angustifolius subsp. transcarpathicus (Amaryllidaceae). Phytochemistry 60 (2002) 847-852
27. Lee J.S., Kim H.J., and Lee Y.S. A new anti-HIV flavonoid glucuronide from Chrysanthemum morifolium. Planta Med 69 (2003) 859-861
28. Litchfield J.T., and Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96 (1949) 99-113
29. Liu J., Hu W.X., He L.F., Ye M., and Li Y. Effects of lycorine on HL-60 cells via arresting cell cycle and inducing apoptosis. FEBS Lett 578 (2004) 245-250
30. Lopez S., Armand-Ugon M., Bastida J., Viladomat F., Este J.A., Stewart D., et al. Anti-human immunodeficiency virus type 1 (HIV-1) activity of lectins from Narcissus species. Planta Med 69 (2003) 109-112
31. Lopez S., Bastida J., Viladomat F., and Codina C. Galanthamine pattern in Narcissus confusus plants. Planta Med 69 (2003) 1166-1168
32. Malawska B. Application of pharmacophore models for the design and synthesis of new anticonvulsant drugs. Mini Rev Med Chem 3 (2003) 341-348
33. Martijena L.D., Garcia R.H., Marin R.H., and Perillo M.A. Anxiogenic-like and antidepressant-like effects of the essential oil from Tagetes minuta. Fitoterapia 2 (1998) 155-160
34. Masur J., Martz R.M.W., and Carlini E.A. Effects of acute and chronic administration of Cannabis sativa and (-) α9-trans-tetrahydrocannabinol on the behavior of rats in an open field arena. Psychopharmacology 19 (1971) 338-397
35. Matthews K., Christmas D., Swan J., and Sorrell E. Animal models of depression: navigating through the clinical fog. Neurosci Biobehav Rev 29 (2005) 503-513
36. McLachlan A., Kekre N., McNulty J., and Pandey S. Pancratistatin: a natural anti-cancer compound that targets mitochondria specifically in cancer cells to induce apoptosis. Apoptosis 10 (2005) 619-630
37. Morais L.C.S.L., Barbosa-Filho J.M., and Almeida R.N. Central depressant effects of reticuline extracted from Ocotea duckei in rats and mice. J Ethnopharmacol 62 (1998) 57-61
38. Nic D.B.A., Bourin M., and Hascoet M. Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety. Behav Brain Res 140 (2003) 203-214
39. Onofri S., Barreca D., and Garuccio I. Effects of lycorine on growth and effects of l-galactonic acid-gamma-lactone on ascorbic acid biosynthesis in strains of Cryptococcus laurentii isolated from Narcissus pseudonarcissus roots and bulbs. Antonie Van Leeuwenhoek 83 (2003) 57-61
40. Pellow S., and File S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav 24 (1986) 525-529
41. Pellow S., and File S.E. Lack of cross-tolerance in mice between the stimulatory and depressant actions of novel anxiolytics in the holeboard. Behav Brain Res 23 (1987) 159-166
42. Perucca E. An introduction to antiepileptic drugs. Epilepsia 46 (2005) 31-37
43. Poleszak E., Wlaz P., Szewczyk B., Kedzierska E., Wyska E., Librowski T., et al. Enhancement of antidepressant-like activity by joint administration of imipramine and magnesium in the forced swim test: behavioral and pharmacokinetic studies in mice. Pharmacol Biochem Behav 81 (2005) 524-529
44. Porsolt R.D., Anton G., Blavet N., and Jalfre M. Behavioral despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47 (1978) 379-391
45. Porsolt R.D., Bertin A., and Jalfre M. "Behavioural despair" in rats and mice: strain differences and the effects of imipramine. Eur J Pharmacol 51 (1978) 291-294
46. Raskind M.A., Peskind E.R., Wessel T., and Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 54 (2000) 2261-2268
47. Rode F., Jensen D.G., Blackburn-Munro G., and Bjerrum O.J. Centrally-mediated antinociceptive actions of GABA(A) receptor agonists in the rat spared nerve injury model of neuropathic pain. Eur J Pharmacol 516 (2005) 131-138
48. Rodgers R.J., Cole J.C., Aboualfa K., and Stephenson L.H. Ethopharmacological analysis of the effects of putative 'anxiogenic' agents in the mouse elevated plus-maze. Pharmacol Biochem Behav 52 (1995) 805-813
49. Szlavik L., Gyuris A., Minarovits J., Forgo P., Molnar J., and Hohmann J. Alkaloids from Leucojum vernum and antiretroviral activity of Amaryllidaceae alkaloids. Planta Med 70 (2004) 871-873
50. Takeda H., Tsuji M., and Matsumiya T. Changes in head-dipping behavior in the hole-board test reflect the anxiogenic and/or anxiolytic state in mice. Eur J Pharmacol 350 (1998) 21-29
51. Thomsen T., and Kewitz H. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci 46 (1990) 1553-1558
52. Thomsen T., Bickel U., Fischer J.P., and Kewitz H. Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans. Eur J Clin Pharmacol 39 (1990) 603-605
53. Wesolowska A., Nikiforuk A., Stachowicz K., and Tatarczynska E. Effect of the selective 5-HT(7) receptor antagonist SB 269970 in animal models of anxiety and depression. Neuropharmacology 51 (2006) 578-586
54. Wilkinson D.G., Francis P.T., Schwam E., and Payne-Parrish J. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging 21 (2004) 453-478
55. Wolfman C., Viola H., Marder M., Wasowski C., Ardenghi P., Izquierdo I., et al. Anxioselective properties of 6,3′-dinitroflavone, a high-affinity benzodiazepine receptor ligand. Eur J Pharmacol 318 (1996) 23-30
56. Zwanzger P., and Rupprecht R. Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. J Psychiatry Neurosci 30 (2005) 167-175